(Q33809615)

29 July 2017

1 reference

title

Early predictors of response to treatment in patients with chronic hepatitis C. (English)

1 reference

29 July 2017

1 reference

Civeira MP

1

1 reference

PubMed ID

10622595

29 July 2017

Prieto J

series ordinal

2

1 reference

29 July 2017

1 January 1999

1 reference

29 July 2017

Journal of Hepatology

1 reference

29 July 2017

31 Suppl 1

1 reference

29 July 2017

237-243

1 reference

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Serum HCV RNA titer at the end of interferon therapy predicts the long-term outcome of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Factors predictive of a beneficial response to therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Significance of early measurement of serum hepatitis C virus RNA in predicting response to interferon therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Usefulness of HCV-RNA assays in efficacy evaluation of interferon treatment for chronic hepatitis C: Amplicor HCV assay and branched DNA probe assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Importance of pretreatment viral load and monitoring of serum hepatitis C virus RNA in predicting responses to interferon-alpha2a treatment of chronic hepatitis C. Hanshin Chronic Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Should patients with early loss of serum HCV-RNA during alpha interferon therapy for chronic hepatitis C be treated for 6 or 12 months?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980409-7

7 January 2021

10.1016/S0168-8278(99)80409-7

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10622595